Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval
- PMID: 1623896
- DOI: 10.1007/BF00265918
Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval
Abstract
Recent reports have suggested an association between terodiline hydrochloride and cardiac arrhythmias. We report 4 patients presenting over a six month period who developed polymorphic ventricular tachycardia (polymorphic VT) while receiving treatment with this agent. In each case there was prolongation of QT interval on electrocardiogram (ECG). Two patients had hypokalaemia associated with diuretic therapy. In the 3 cases in which follow-up ECG was available, QT interval returned to normal after discontinuation of terodiline. In order to define the effects of terodiline on corrected QT interval (QTc) and heart rate in the elderly, a prospective study was performed in 8 elderly in-patients treated with terodiline for urinary incontinence. After 7 days treatment with terodiline 12.5 mg twice daily, there was a significant increase in QT by a mean of 29 ms, QTc by 15 ms and a decrease in resting heart rate by a mean of 6.7 beats.min-1. Terodiline increases QTc and reduces resting heart rate in elderly patients. Both these effects may be associated with polymorphic VT, a potentially life threatening arrhythmia. This drug should be avoided in patients with other known risk factors for polymorphic VT, particularly hypokalaemia and cardiac disease.
Similar articles
-
Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.Br Heart J. 1995 Jul;74(1):53-6. doi: 10.1136/hrt.74.1.53. Br Heart J. 1995. PMID: 7662454 Free PMC article.
-
[Polymorph ventricular tachycardia with torsades de pointes caused by administration of terodiline (Mictrol)].Ned Tijdschr Geneeskd. 1992 Jan 11;136(2):91-3. Ned Tijdschr Geneeskd. 1992. PMID: 1370730 Dutch.
-
[Clinical study of terodiline hydrochloride for the treatment of urinary frequency and urinary incontinence, and its cardiovascular adverse effects].Hinyokika Kiyo. 1992 Aug;38(8):967-72. Hinyokika Kiyo. 1992. PMID: 1414748 Japanese.
-
Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.Drugs. 1990 Nov;40(5):748-61. doi: 10.2165/00003495-199040050-00008. Drugs. 1990. PMID: 2292235 Review.
-
Functional daytime incontinence: pharmacological treatment.Scand J Urol Nephrol Suppl. 1992;141:108-14; discussion 115-6. Scand J Urol Nephrol Suppl. 1992. PMID: 1609246 Review.
Cited by
-
The Q-T interval and antimuscarinic drugs.Curr Urol Rep. 2005 Nov;6(6):405-9. doi: 10.1007/s11934-005-0033-2. Curr Urol Rep. 2005. PMID: 16238912 Review.
-
Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.Br J Pharmacol. 2000 Sep;131(2):245-54. doi: 10.1038/sj.bjp.0703595. Br J Pharmacol. 2000. PMID: 10991917 Free PMC article.
-
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.Br J Clin Pharmacol. 2000 Jul;50(1):77-80. doi: 10.1046/j.1365-2125.2000.00230.x. Br J Clin Pharmacol. 2000. PMID: 10886124 Free PMC article.
-
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.Br J Clin Pharmacol. 2011 Aug;72(2):186-96. doi: 10.1111/j.1365-2125.2010.03813.x. Br J Clin Pharmacol. 2011. PMID: 21595741 Free PMC article. Review.
-
The problems of anticholinergic adverse effects in older patients.Drugs Aging. 1993 Jul-Aug;3(4):335-48. doi: 10.2165/00002512-199303040-00004. Drugs Aging. 1993. PMID: 8369593 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous